Article Per Year (5 Year)
p-Index From 2020 - 2025
0.61
P-Index
This Author published in this journals
All Journal Bali Dermatology and Venereology Journal Essential: Essence of Scientific Medical Journal Bali Dermatology Venereology and Aesthetic Journal
Anak Agung Bagus Putra Indrakusuma
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Public Health

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Kombinasi Nanopartikel Quercetin-Kaempferol Berpolimer Kitosan sebagai Penatalaksanaan Kanker Kolorektal Anak Agung Bagus Putra Indrakusuma; Aizar Vesa Prasetyo; Nareswara Pawestri; Ketut Adhi Pramana Sinardja
Essence of Scientific Medical Journal Vol 19 No 2 (2021): Volume 19 No. 2 (Juli - Desember 2021) Essential: Essence of Scientific Medical
Publisher : Kelompok Ilmiah Hippocrates Fakultas Kedokteran Universitas Udayana

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24843/ESTL.2021.v19.i02.p02

Abstract

ABSTRAK Pendahuluan: Kanker kolorektal merupakan jenis kanker yang berasal dari jaringan usus besar. Kanker kolorektal telah mengakibatkan 2 juta kasus baru dan 1 juta kematian secara global. Di Indonesia, prevalensi kanker kolorektal adalah 12,8% per 100.000 penduduk usia dewasa dengan mortalitas sebesar 9,5%. Penanganan kanker kolorektal saat ini seperti pembedahan, radioterapi, dan pemberian obat anti-kanker dinilai kurang efektif karena mahal dan memicu efek samping. Pembahasan: Quercetin dan kaempferol merupakan zat flavonoid yang dapat mengobati kanker kolorektal melalui serangkaian mekanisme pada tahapan proses karsinogenesis, yaitu menghalangi proliferasi dengan menghambat NF-kB, meningkatkan proses apoptosis dengan memengaruhi gen CASP2, CLEC4M, dan NTR3K, serta menimbulkan efek antiangiogenesis dengan menurunkan ekspresi MMP-2 dan MMP-9. Keterbatasan modalitas ini ialah rendahnya bioavailabilitasnya sehingga dikemas dalam bentuk nanopartikel berpolimer kitosan. Quercetin terbanyak diperoleh dari kulit bawang sedangkan kaempferol diperoleh dari daun bawang. Pembuatan nanopartikel kitosan quercetin-kaempferol menggunakan metode top down (maserasi). Modalitas ini diadministrasikan secara oral. Kitosan sebagai polimer akan larut saat memasuki asam lambung. Farmakokinetik dari modalitas akan dimulai dengan absorpsi oleh usus halus dan diakhiri oleh ekskresi oleh ginjal serta eliminasi oleh usus besar. Quercetin 15 ?M-30 ?M mampu menurunkan cell viability menjadi 63 ± 1,3% hingga 41 ± 0,3%. Sedangkan, kaempferol 30 ?M-60 ?M mampu menurunkan cell viability menjadi 62 ± 0,83% hingga 26 ± 0,91%. Simpulan: Kombinasi quercetin dan kaempferol dapat meningkatkan proses apoptosis secara eksternal maupun internal serta menghambat proliferasi dan angiogenesis sel kanker kolorektal. Kata kunci: Kanker kolorektal, Quercetin, Kaempferol
Focus on the dabrafenib, vemurafenib, and trametinib in clinical outcome of melanoma: a systematic review and meta-analysis Ida Ayu Widya Anjani; Anak Agung Bagus Putra Indrakusuma; I Gede Krisna Arim Sadeva; Putri Ayu Wulandari; Luh Made Mas Rusyati; Prima Sanjiwani Saraswati Sudarsa; I Gede Putu Supadmanaba; Desak Made Wihandani
Bali Dermatology and Venereology Journal Vol. 3 No. 2 (2020)
Publisher : DiscoverSys Inc

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15562/bdv.v3i2.38

Abstract

Background: Melanoma is the most serious lethal skin cancer, affects the melanin producer cells (melanocytes). Surgery is the most common treatment, whereas for the advance stage the development of a treatment is recommended. BRAF (Dabrafenib and Vemurafenib) inhibitor or MEK inhibitor (Trametinib) is used as the most frequently targeted therapy of melanoma due to more than 80% patient with positive BRAF mutation. In this review, those treatments will be investigated systematically to identify their clinical outcome.Method: This systematic literature review (SLR) was performed from Cochrane, Science Direct, Google Scholar, and Pubmed. Cochrane Risk-of-Bias Tool RoB2 is used to assess RCT studies and New-castle Ottawa Scale Assessment to assess cohort studies by 3 different assessors. Data analysis was carried out by using Review Manager (RevMan 5.4). Heterogenicity test was assessed by I2  and Chi2 statisticResult: There are 20 studies used in this article (13 RCT and 7 cohorts). The overall survival (OS) and progression-free survival (PFS) of study that using targeted therapy (vemurafenib, trametinib, or dabrafenib) compare other therapies (chemotherapy, immunotherapy,etc) showed risk ratio (RR) was 1.12 (95%CI 1.07,1.17;  I2=100%; p<0,00001). The OS and PFS with monotherapy compare of vemurafenib, trametinib, or dabrafenib with combination therapy showed RR was 1.09 (95%CI.06,1.13;I2=99%; p<0,00001). Conclusion: BRAF and MEK targeted therapy has a good prognosis for a patient with a positive BRAF gene mutation and could be combined with other therapy for a better clinical outcome rather than monotherapy.Keyword: melanoma, dabrafenib, vemurafenib, and trametinib
Focus on the dabrafenib, vemurafenib, and trametinib in the clinical outcome of melanoma: A systematic review and meta-analysis Ida Ayu Widya Anjani; Anak Agung Bagus Putra Indrakusuma; I Gede Krisna Arim Sadeva; Putri Ayu Wulandari; Luh Made Mas Rusyanti; Prima Sanjiwani Saraswati Sudarsa; I Gede Putu Supadmanaba; Desak Made Wihandani
Bali Dermatology Venereology and Aesthetic Journal BDVJ - Vol. 3 No. 2 (December 2020)
Publisher : Explorer Front

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.51559/myphje28

Abstract

Background: Melanoma is the most severe lethal skin cancer, affecting melanin producer cells (melanocytes). Surgery is the most common treatment, whereas, for the advanced stage, the development of treatment is recommended. BRAF (Dabrafenib and Vemurafenib) inhibitor or MEK inhibitor (Trametinib) is the most frequently targeted melanoma therapy due to more than 80% of patients with positive BRAF mutation. In this review, those treatments will be investigated systematically to identify their clinical outcome. Method: This systematic literature review (SLR) was performed from Cochrane, Science Direct, Google Scholar, and Pubmed. Cochrane Risk-of-Bias Tool RoB2 is used to assess RCT studies and New-castle Ottawa Scale Assessment to assess cohort studies by three different assessors. Data analysis was carried out by using Review Manager (RevMan 5.4). Heterogenicity test was assessed by I2 and Chi2 statistic Result: There are 20 studies used in this article (13 RCT and seven cohorts). The overall survival (OS) and progression-free survival (PFS) of the survey that using targeted therapy (vemurafenib, trametinib, or dabrafenib) compare other treatments (chemotherapy, immunotherapy, etc.) showed risk ratio (RR) was 1.12 (95%CI 1.07,1.17; I2=100%; p<0,00001). The OS and PFS with monotherapy compare of vemurafenib, trametinib, or dabrafenib with combination therapy showed RR was 1.09 (95%CI.06,1.13; I2=99%; p<0,00001). Conclusion: BRAF and MEK targeted therapy has a good prognosis for a patient with a positive BRAF gene mutation and could be combined with other treatments for better clinical outcomes rather than monotherapy.
Co-Authors Aizar Vesa Prasetyo Desak Made Wihandani I G. P. Supadmanaba I Gede Krisna Arim Sadeva Ida Ayu Widya Anjani Ida Ayu Widya Anjani Ketut Adhi Pramana Sinardja Luh Made Mas Rusyanti Luh Made Mas Rusyati Nareswara Pawestri Prima Saraswati Sanjiwani Sudarsa Putri Ayu Wulandari